

Craig C Hofmeister

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9487069/publications.pdf>

Version: 2024-02-01

241
papers

8,883
citations

70961

41
h-index

46693

89
g-index

244
all docs

244
docs citations

244
times ranked

11386
citing authors

#	ARTICLE	IF	CITATIONS
1	Initial genome sequencing and analysis of multiple myeloma. <i>Nature</i> , 2011, 471, 467-472.	13.7	1,288
2	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1770-1781.	13.9	1,024
3	The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. <i>Blood</i> , 2010, 116, 2286-2294.	0.6	716
4	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. <i>Blood</i> , 2014, 123, 1826-1832.	0.6	327
5	Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1841-1849.	2.0	258
6	A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2012, 120, 4324-4333.	0.6	217
7	Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche. <i>Bone Marrow Transplantation</i> , 2007, 39, 11-23.	1.3	190
8	IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. <i>Blood</i> , 2011, 118, 6387-6391.	0.6	184
9	Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 230-269.	2.3	166
10	A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4055-4061.	3.2	154
11	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1928-1937.	0.8	148
12	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 11-20.	2.3	142
13	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e431-e442.	2.2	132
14	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. <i>Journal of Experimental Medicine</i> , 2013, 210, 951-968.	4.2	121
15	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. <i>Nature Communications</i> , 2019, 10, 1911.	5.8	109
16	Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy. <i>JCI Insight</i> , 2019, 4, .	2.3	107
17	Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. <i>Blood</i> , 2018, 131, 855-863.	0.6	105
18	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. <i>Blood Cancer Journal</i> , 2019, 9, 94.	2.8	104

#	ARTICLE	IF	CITATIONS
19	Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells. <i>Clinical Cancer Research</i> , 2014, 20, 3989-4000.	3.2	103
20	Daratumumab in multiple myeloma. <i>Cancer</i> , 2019, 125, 2364-2382.	2.0	100
21	Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1422-1430.	2.0	89
22	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. <i>Blood</i> , 2011, 118, 535-543.	0.6	82
23	MicroRNAs activate natural killer cells through Toll-like receptor signaling. <i>Blood</i> , 2013, 121, 4663-4671.	0.6	82
24	Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein. <i>Journal of Clinical Oncology</i> , 2011, 29, 3427-3434.	0.8	77
25	A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2014, 20, 5946-5955.	3.2	72
26	Symphony: view-driven software architecture reconstruction. , 0, , .		68
27	Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis following Allogeneic Peripheral Blood Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 783-789.	2.0	68
28	Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. <i>Journal of Proteomics</i> , 2016, 136, 89-98.	1.2	68
29	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. <i>Blood</i> , 2016, 127, 2693-2700.	0.6	66
30	Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. <i>Journal of Geriatric Oncology</i> , 2019, 10, 479-485.	0.5	64
31	Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1658-1664.	0.6	63
32	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 389-400.	2.3	62
33	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. <i>Leukemia</i> , 2021, 35, 189-200.	3.3	56
34	Retrospective utility of bronchoscopy after hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2006, 38, 693-698.	1.3	55
35	Circulating miRNA markers show promise as new prognosticators for multiple myeloma. <i>Leukemia</i> , 2014, 28, 1922-1926.	3.3	55
36	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). <i>Leukemia</i> , 2020, 34, 1840-1852.	3.3	55

#	ARTICLE	IF	CITATIONS
37	Multiple Myeloma, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1398-1435.	2.3	55
38	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia, 2020, 34, 2430-2440.	3.3	54
39	Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplantation, 2016, 51, 1241-1244.	1.3	53
40	Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia, 2018, 32, 2495-2518.	3.3	53
41	Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer, 2001, 92, 2334-2340.	2.0	51
42	The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo. PLoS ONE, 2010, 5, e10941.	1.1	49
43	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood, 2021, 137, 3604-3615.	0.6	44
44	A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leukemia and Lymphoma, 2017, 58, 2310-2318.	0.6	43
45	Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. British Journal of Cancer, 2014, 111, 272-280.	2.9	42
46	Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. OncoImmunology, 2018, 7, e1486948.	2.1	41
47	Allogeneic Stem Cell Transplantation for Patients with Relapsed Chemorefractory Aggressive Non-Hodgkin Lymphomas. Biology of Blood and Marrow Transplantation, 2009, 15, 547-553.	2.0	39
48	HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget, 2015, 6, 31134-31150.	0.8	38
49	Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma. Bone Marrow Transplantation, 2015, 50, 1379-1381.	1.3	36
50	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer, 2019, 125, 416-423.	2.0	36
51	Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 110-112.	1.4	35
52	Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. Molecular Cancer Therapeutics, 2016, 15, 830-841.	1.9	35
53	Tocilizumab for steroid refractory acute graft-versus-host disease. Leukemia and Lymphoma, 2016, 57, 81-85.	0.6	35
54	Graft-versus-host disease of the skin: life and death on the epidermal edge. Biology of Blood and Marrow Transplantation, 2004, 10, 366-372.	2.0	34

#	ARTICLE	IF	CITATIONS
55	Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. <i>Lancet Haematology</i> , 2017, 4, e24-e34.	2.2	33
56	Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Molecular Therapy - Oncolytics</i> , 2017, 5, 87-96.	2.0	33
57	MiR-16 regulates crosstalk in NF- κ B tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. <i>JCI Insight</i> , 2019, 4, .	2.3	33
58	Characterization of Multiple Myeloma Vesicles by Label-Free Relative Quantitation. <i>Proteomics</i> , 2013, 13, n/a-n/a.	1.3	32
59	Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104. <i>Blood</i> , 2010, 116, 37-37.	0.6	31
60	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3057-3064.	0.8	31
61	A phase I trial of flavopiridol in relapsed multiple myeloma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 249-257.	1.1	30
62	Twice-weekly ixazomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 231-244.	1.2	30
63	Polymorphism in <i>ANRIL</i> is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. <i>Molecular Carcinogenesis</i> , 2017, 56, 1722-1732.	1.3	28
64	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 302-302.	0.6	28
65	Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 620-627.	1.0	27
66	The potential of miRNAs as biomarkers for multiple myeloma. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 947-959.	1.5	23
67	Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 658-668.	2.0	23
68	A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. <i>British Journal of Haematology</i> , 2016, 174, 323-325.	1.2	22
69	The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma. <i>Bone Marrow Transplantation</i> , 2014, 49, 1323-1329.	1.3	21
70	Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 262-268.	1.4	21
71	Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. <i>British Journal of Haematology</i> , 2015, 171, 74-83.	1.2	20
72	How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4421-4430.	0.8	20

#	ARTICLE	IF	CITATIONS
73	Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR. <i>Bone Marrow Transplantation</i> , 2007, 39, 249-251.	1.3	19
74	Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 1058-1065.	0.6	19
75	Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2018, 53, 1418-1427.	1.3	19
76	Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma. <i>Blood</i> , 2008, 112, 2770-2770.	0.6	19
77	Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data. <i>Blood</i> , 2013, 122, 535-535.	0.6	18
78	TTP disease course is independent of myeloma treatment and response. <i>American Journal of Hematology</i> , 2010, 85, 304-306.	2.0	17
79	FLT3L and Plerixafor Combination Increases Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 309-313.	2.0	17
80	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 599-611.	1.1	16
81	Clinical Utility of Autopsy after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 26-30.	2.0	15
82	Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 243-251.	0.6	15
83	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 3178-3189.	3.2	15
84	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. <i>Blood Cancer Discovery</i> , 2021, 2, 600-615.	2.6	15
85	Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM). <i>Journal of Clinical Oncology</i> , 2015, 33, 8523-8523.	0.8	15
86	Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. <i>Hematological Oncology</i> , 2011, 29, 202-210.	0.8	14
87	Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. <i>Supportive Care in Cancer</i> , 2014, 22, 2911-2916.	1.0	14
88	Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. <i>Laryngoscope Investigative Otolaryngology</i> , 2021, 6, 1008-1019.	0.6	14
89	Induced Resistance to Bortezomib in Preclinical Model of Waldenstrom Macroglobulinemia Is Associated with Bcl-2 Upregulation. <i>Blood</i> , 2009, 114, 4919-4919.	0.6	14
90	Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2009, 114, 431-431.	0.6	13

#	ARTICLE	IF	CITATIONS
91	A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia., Blood, 2011, 118, 3701-3701.	0.6	13
92	Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leukemia Research, 2008, 32, 1295-1298.	0.4	12
93	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). Blood, 2013, 122, 1969-1969.	0.6	12
94	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). Blood, 2015, 126, 3036-3036.	0.6	12
95	Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial. Blood, 2016, 128, 1346-1346.	0.6	12
96	Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). Biology of Blood and Marrow Transplantation, 2016, 22, 71-79.	2.0	11
97	Pharmacokineticâ€Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving Highâ€Dose Melphalan for Autologous Stem Cell Transplant. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 748-758.	1.3	11
98	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. European Journal of Haematology, 2019, 102, 494-503.	1.1	11
99	Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. Blood, 2018, 132, 3282-3282.	0.6	11
100	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. Blood, 2012, 120, 450-450.	0.6	11
101	First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2015, 126, 1838-1838.	0.6	11
102	A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. American Journal of Hematology, 2022, 97, .	2.0	11
103	Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents. Hematological Oncology, 2012, 30, 156-162.	0.8	10
104	A Single Nucleotide Polymorphism in <i>SLC7A5</i> Was Associated With Clinical Response in Multiple Myeloma Patients. Anticancer Research, 2019, 39, 67-72.	0.5	10
105	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). Blood, 2018, 132, 1994-1994.	0.6	10
106	Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial. Blood, 2019, 134, 602-602.	0.6	10
107	A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma. Blood, 2016, 128, 4509-4509.	0.6	10
108	Unique Pattern of Renal Î² Light Chain Amyloid Deposition With Histiocytic Transdifferentiation of Tubular Epithelial Cells. American Journal of Surgical Pathology, 2012, 36, 1253-1257.	2.1	9

#	ARTICLE	IF	CITATIONS
109	BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1107-1115.	2.0	9
110	Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. <i>Blood</i> , 2011, 118, 634-634.	0.6	9
111	MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 727-727.	0.6	9
112	Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 728-728.	0.6	9
113	Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma. <i>Blood</i> , 2010, 116, 3564-3564.	0.6	9
114	Mucosal protection by cytokines. <i>Psychophysiology</i> , 2005, 4, 446-53.	1.1	9
115	The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 351-352.	2.0	8
116	Chemotherapeutic Agents Increase the Risk for Pulmonary Function Test Abnormalities in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 325-329.	0.2	8
117	Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer. <i>Medical Oncology</i> , 2013, 30, 358.	1.2	8
118	Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization. <i>Leukemia Research</i> , 2019, 85, 106215.	0.4	8
119	Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 924-934.	1.1	8
120	Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 519-531.	2.0	8
121	Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events. <i>Blood</i> , 2009, 114, 3416-3416.	0.6	8
122	Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma. <i>Blood</i> , 2013, 122, 1853-1853.	0.6	8
123	Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 4773-4773.	0.6	8
124	TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 3052-3052.	0.6	8
125	Evaluation of pulmonary infiltrates in patients after stem cell transplantation. <i>Hematology</i> , 2005, 10, 469-481.	0.7	7
126	A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1043-1049.	0.6	7

#	ARTICLE	IF	CITATIONS
127	XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. <i>Molecular Carcinogenesis</i> , 2019, 58, 2327-2339.	1.3	7
128	Downregulation of PA28 induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 125.	2.8	7
129	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. <i>American Journal of Hematology</i> , 2021, 96, E68-E71.	2.0	7
130	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.. <i>Blood</i> , 2009, 114, 132-132.	0.6	7
131	The Majority of Myeloma Patients Are Vitamin D Deficient, Unrelated to Survival or Cytogenetics. <i>Blood</i> , 2015, 126, 5336-5336.	0.6	7
132	Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma.. <i>Blood</i> , 2009, 114, 2884-2884.	0.6	7
133	BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. <i>Bone Marrow Transplantation</i> , 2019, 54, 1553-1561.	1.3	6
134	Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial. <i>Blood</i> , 2018, 132, 123-123.	0.6	6
135	Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH) Tj ETQq1 1 0.784314 rgBT /Overl... 2010, 116, 3966-3966.	0.6	6
136	Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Blood</i> , 2012, 120, 1942-1942.	0.6	6
137	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publicationsâ€². <i>Mayo Clinic Proceedings</i> , 2010, 85, 197-199.	1.4	5
138	Characterizing Pain Experiences: African American Patients With Multiple Myeloma Taking Around-the-Clock Opioids. <i>Clinical Journal of Oncology Nursing</i> , 2020, 24, 538-546.	0.3	5
139	Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2165-2173.	1.1	5
140	Long Term Therapy with Lenalidomide in a patient with POEMS Syndrome. <i>European Journal of Case Reports in Internal Medicine</i> , 2014, 1, .	0.2	5
141	Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 75.e1-75.e7.	0.6	5
142	A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results. <i>Blood</i> , 2012, 120, 4058-4058.	0.6	5
143	Phase I Adjuvant Radiation With Docetaxel in High-Risk Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 396-400.	0.6	4
144	Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease. <i>Clinical Pharmacokinetics</i> , 2013, 52, 705-712.	1.6	4

#	ARTICLE	IF	CITATIONS
145	G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2947-2951.	0.6	4
146	Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 44-49.	2.0	4
147	Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Anticancer Research</i> , 2020, 40, 5707-5713.	0.5	4
148	Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.. <i>Blood</i> , 2012, 120, 2955-2955.	0.6	4
149	Reolysin Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 1835-1835.	0.6	4
150	Exploring the Possibility of Using Herpes Simplex Virus in Oncolytic Virotherapy of Multiple Myeloma. <i>Blood</i> , 2016, 128, 4467-4467.	0.6	4
151	G-CSF Starting Day +1 after Autologous Transplant Is Safer Than Day +5 or Day +7 in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 5790-5790.	0.6	4
152	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. <i>Blood</i> , 2017, 130, 902-902.	0.6	4
153	A Single Nucleotide Polymorphism (SNP) in the <i>SLC22A3</i> Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy. <i>Anticancer Research</i> , 2022, 42, 385-395.	0.5	4
154	Most multiple myeloma patients have low testosterone. <i>Leukemia and Lymphoma</i> , 2019, 60, 836-838.	0.6	3
155	Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 5647-5647.	0.6	3
156	A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma. <i>Blood</i> , 2013, 122, 3181-3181.	0.6	3
157	2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial. <i>Blood</i> , 2014, 124, 3960-3960.	0.6	3
158	Anti-Depressant Use in Patients with Multiple Myeloma Less Common Than Expected. <i>Blood</i> , 2016, 128, 2420-2420.	0.6	3
159	Daratumumab Impairs Myeloma Cell Adhesion Mediated Drug Resistance through CD38 Internalization. <i>Blood</i> , 2016, 128, 4479-4479.	0.6	3
160	MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8584-8584.	0.8	3
161	Importin-1 ² and exportin-5 are strong biomarkers of productive reoviral infection of cancer cells. <i>Annals of Diagnostic Pathology</i> , 2018, 32, 28-34.	0.6	2
162	Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?. <i>Bone Marrow Transplantation</i> , 2019, 54, 913-916.	1.3	2

#	ARTICLE	IF	CITATIONS
163	Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses. <i>Blood</i> , 2018, 132, 2655-2655.	0.6	2
164	Safety and Efficacy of Evomelaâ„¢ in Myeloma Autotransplants. <i>Blood</i> , 2018, 132, 3446-3446.	0.6	2
165	Efficacy of Induction Therapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2018, 132, 3294-3294.	0.6	2
166	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.. <i>Blood</i> , 2010, 116, 3803-3803.	0.6	2
167	Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance. <i>Blood</i> , 2012, 120, 2004-2004.	0.6	2
168	T-Cell p16INK4A Expression Increases Post-Transplant in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 2023-2023.	0.6	2
169	Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients. <i>Blood</i> , 2015, 126, 3200-3200.	0.6	2
170	Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). <i>Blood</i> , 2014, 124, 1166-1166.	0.6	2
171	Wavelet analysis of SAECG to identify patients with conduction defects at risk for sudden cardiac death. <i>Biomedical Sciences Instrumentation</i> , 1997, 33, 497-502.	0.2	2
172	Reply to N. Chen et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 341-342.	0.8	1
173	Improving Vaccination of Patients Pre and Post Bone Marrow Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S380.	2.0	1
174	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. <i>Blood</i> , 2018, 132, 3241-3241.	0.6	1
175	Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy. <i>Blood</i> , 2018, 132, 1884-1884.	0.6	1
176	Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma. <i>Blood</i> , 2019, 134, 1816-1816.	0.6	1
177	Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials. <i>Blood</i> , 2019, 134, 4525-4525.	0.6	1
178	IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.. <i>Blood</i> , 2009, 114, 3870-3870.	0.6	1
179	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial. <i>Blood</i> , 2010, 116, 1937-1937.	0.6	1
180	Phase I Study of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 1859-1859.	0.6	1

#	ARTICLE	IF	CITATIONS
181	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure. <i>Blood</i> , 2012, 120, 4070-4070.	0.6	1
182	Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD). <i>Blood</i> , 2012, 120, 4192-4192.	0.6	1
183	The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma. <i>Blood</i> , 2012, 120, 4286-4286.	0.6	1
184	Low Testosterone Levels Are Associated with Shorter Progression Free Survival in Multiple Myeloma. <i>Blood</i> , 2012, 120, 4978-4978.	0.6	1
185	A Phase 1 Trial Of Reolysin Alone In Patients With Refractory Or Relapsed Multiple Myeloma. <i>Blood</i> , 2013, 122, 3208-3208.	0.6	1
186	Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 807-816.	0.6	1
187	Autopsies Post Hematopoietic Stem Cell Transplant: A Reassessment of Their Role in Patient Management.. <i>Blood</i> , 2005, 106, 1332-1332.	0.6	1
188	Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results.. <i>Blood</i> , 2009, 114, 2880-2880.	0.6	1
189	IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interim Phase 1 Trial Results and Correlative Biologic and Safety Data. <i>Blood</i> , 2010, 116, 1966-1966.	0.6	1
190	Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia. <i>Blood</i> , 2010, 116, 1933-1933.	0.6	1
191	Development of a Predictive Pharmacokinetic and Pharmacodynamic Model to Personalize Melphalan Dosing in Autologous Transplant for Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 1086-1086.	0.6	1
192	HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide. <i>Blood</i> , 2014, 124, 3377-3377.	0.6	1
193	The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study. <i>Blood</i> , 2018, 132, 5911-5911.	0.6	1
194	Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies. <i>Blood</i> , 2021, 138, 3134-3134.	0.6	1
195	Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. <i>Pharmacotherapy</i> , 2022, 42, 233-240.	1.2	1
196	Title is missing!. <i>Cardiovascular Engineering (Dordrecht, Netherlands)</i> , 2002, 2, 33-35.	1.0	0
197	Impact of Atorvastatin On Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S202.	2.0	0
198	Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis). <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S186.	2.0	0

#	ARTICLE	IF	CITATIONS
199	Improved Survival of Patients (Pts) with Acute Graft-Versus-Host Disease (aGVHD) During Recent Years: Impact of Donor and Recipient Characteristics. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S320-S321.	2.0	0
200	Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoietic Stem Cell Transplant (HSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S304-S305.	2.0	0
201	High-Risk Myeloma: When To Transplant Or Not. <i>Seminars in Oncology</i> , 2014, 41, e1-e9.	0.8	0
202	Utility of CMV PCR in the Evaluation of Allograft Recipients Presenting with Diarrhea. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S250-S251.	2.0	0
203	A Potential Role for Auto-Graft Immune Cell Subsets to Influence Post-Transplant Outcomes in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S131.	2.0	0
204	Phase 1/2 dose-escalation study of marizomib (MRZ, NPI-0052) plus low dose dexamethasone (DEX) in patients with relapsed and refractory multiple myeloma; study NPI-0052-101 (NCT00461045). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e271-e272.	0.2	0
205	Antithymocyte Globulin (ATG) 4.5 Vs. 6.0 Mg/Kg in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S316-S317.	2.0	0
206	Registering a CD38 antibody upfront for multiple myeloma. <i>Lancet, The</i> , 2019, 394, 3-4.	6.3	0
207	The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Patients with Multiple Myeloma.. <i>Blood</i> , 2007, 110, 5129-5129.	0.6	0
208	Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (MM) Patients: Burden of Illness and Patterns of Care. <i>Blood</i> , 2008, 112, 2409-2409.	0.6	0
209	Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2008, 112, 2170-2170.	0.6	0
210	Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkin's Lymphomas.. <i>Blood</i> , 2008, 112, 3265-3265.	0.6	0
211	Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 4641-4641.	0.6	0
212	p53-Inducible Micrnas 192 and 215 Regulate p53 Expression and IGF1 Axis in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 1973-1973.	0.6	0
213	Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study. <i>Blood</i> , 2010, 116, 1343-1343.	0.6	0
214	Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors.. <i>Blood</i> , 2010, 116, 3807-3807.	0.6	0
215	The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. <i>Blood</i> , 2011, 118, 1024-1024.	0.6	0
216	Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma. <i>Blood</i> , 2012, 120, 4460-4460.	0.6	0

#	ARTICLE	IF	CITATIONS
217	miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.. Blood, 2012, 120, 2921-2921.	0.6	0
218	Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease. Blood, 2012, 120, 1949-1949.	0.6	0
219	Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma.. Blood, 2012, 120, 3114-3114.	0.6	0
220	FLT3L and AMD3100 Combination Increases Hematopoietic Stem Cell Mobilization and Leads To Improved Transplantation Outcome. Blood, 2013, 122, 901-901.	0.6	0
221	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). Blood, 2013, 122, 3185-3185.	0.6	0
222	Understanding The Differential Response Of Multiple Myeloma To Reovirus Treatment. Blood, 2013, 122, 3232-3232.	0.6	0
223	Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 2494-2494.	0.6	0
224	Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT). Blood, 2014, 124, 3929-3929.	0.6	0
225	Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers. Blood, 2015, 126, 1814-1814.	0.6	0
226	The Majority of Myeloma Patients Are Hypogonadal but This Is Not Associated with High Risk Cytogenetics. Blood, 2015, 126, 5329-5329.	0.6	0
227	Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development. Blood, 2015, 126, 1791-1791.	0.6	0
228	Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). Blood, 2015, 126, 4328-4328.	0.6	0
229	Relative Clone Size By FISH of Both Del(13q) and Del(17p) Independently Impact Overall Survival. Blood, 2016, 128, 4444-4444.	0.6	0
230	Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation. Blood, 2016, 128, 3409-3409.	0.6	0
231	Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 1241-1241.	0.6	0
232	Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation. Blood, 2016, 128, 3410-3410.	0.6	0
233	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. Blood, 2018, 132, 3302-3302.	0.6	0
234	The Role of Proteasome Activator PA28Î± in Multiple Myeloma. Blood, 2019, 134, 5499-5499.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) Tj ETQq1 1 0.784314 rgBT /Over	0.6	0
236	Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients. Blood, 2021, 138, 1616-1616.	0.6	0
237	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. Blood, 2021, 138, 1624-1624.	0.6	0
238	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.6	0
239	Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma. Blood, 2020, 136, 31-32.	0.6	0
240	Role of clonoSEQ [®] , a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma. Blood, 2020, 136, 50-51.	0.6	0
241	Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT).. , 2019, 2, 12-18.		0